Dr. Hisham Al-Ghazali, Professor of Oncology and President of the International Society of Oncology, said that the conference this year presents more than 300 scientific and research papers and 15 themes, including: immunotherapy for tumors, pathology, radiology, surgery, analyzes, genetic examinations, and cancer research.Al-Ghazali added, in a statement today, Tuesday, that for the first time an accredited certificate is granted to those present in advanced ovarian tumors accredited by the European Society of Gynecological Oncology outside Europe, and an accredited program for liquid DNA sample analysis, diagnosis and follow-up of tumors accredited by the International Society for DNA Analysis. The scientific program for the two conferences was also accredited by the American Association for Medical Education. The conference also included several skill workshops for sampling using radiology for breast tumors, bronchoscopy, pathological analysis, and workshops for internal radiation therapy with the accreditation of the European Society for Radiotherapy Oncology. The President of the International Society of Oncology also mentioned that 5 new drugs will be launched for breast, lung and ovarian tumors, including the launch of a new drug to treat the BRCA gene, which is present in various types of breast cancer, especially triple-negative breast tumors, which were difficult to treat diseases, and activates the protein responsible for treating The DNA of women with the disease, and studies led to its superiority over several types of chemotherapy treatments in advanced breast tumors, and the cure rates doubled compared to chemotherapy. He stressed that other treatments for Barb DNA will be launched, and it can be used in ovarian tumors after the initial response to platinum chemical drugs and advanced ovarian tumors in the second line, and it has been used in breast tumors in patients who have a mutation of the Praca gene, in addition to launching a new drug in the treatment of breast cancer. Lung and knowledge of new genetic mutations, including the alk genetic mutation, which is found in lung cancer by 7%. A new treatment has appeared that treats this type of lung tumors, especially lung tumors that spread to the brain, and it led to a strong improvement and response in this type of tumors, and showed that 76% The disease led to a complete response despite the presence of this spread in the brain, and the average response was within a month from the start of treatment, and the response in the treatment of secondary brain tumors was 82%.
